Titlebook: Management of Advanced Prostate Cancer; Choung Soo Kim Book 2018 Springer Nature Singapore Pte Ltd. 2018 Prostate Cancer.radiotherapy.chem

Juvenile

Champion

Robot-Assisted Radical Prostatectomy for High-Risk Prostate Cancerare 3 times and 11 times higher, respectively. Therefore, high-risk patients are treated with multimodal approaches, including surgery. But, evidences supporting surgery as a monotherapy and showing optimal results has emerged recently. In a current review comapring robot-assisted radical prostatect

輕彈

Pelvic Lymphadenectomy for High-Risk Prostate Cancers with prostate cancer. In the treatment of prostate cancer, however, the clinical benefit of pelvic lymphadenectomy is debatable. In the past, it was common practice not to conduct radical prostatectomy when the lymph node positive results were seen in the frozen section during surgery [.]. Despite

替代品

Adjuvant Therapy in Locally Advanced Prostate Cancererapy. Adjuvant radiotherapy (RT) and adjuvant hormonal therapy (HT) could be included as treatment options. In considering therapeutic options for treating HT, both short-term therapy and long-term therapy could be included. Generally, current evidence supports surgical intervention (radical prosta

搬運(yùn)工

徹底檢查

aspersion

伸展

Emerging Role of Radiotherapy in Stage IV Prostate Cancerr patients with survival benefit compared with convention hormonal therapy alone. Also, small retrospective studies suggested metastasis-directed therapy using stereotactic radiation therapy (SBRT) in oligometastatic setting could provide excellent local control, progression free survival advantage

飛來飛去真休

Adjuvant and Salvage Radiation Therapy for Prostate Cancer After Radical Prostatectomyually with elevated prostate-specific antigen (PSA) level [1, 2]. Postoperative radiation therapy is recommended for patients with adverse risk factors after complete surgical resection, subclinical disease detected by elevated postoperative serum PSA, or clinical tumor recurrence in prostatic fossa

絆住

Immediate vs. Delayed ADT for Recurrent Prostate Cancerostate-specific antigen (PSA) level, a condition known as biochemical recurrence (BCR) [1–3]. Elevations in PSA may indicate local or distant recurrence. Thus, once BCR occurs the patient is presumed to have recurrent prostate cancer. Among patients who develop BCR, approximately one-third will deve